Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

BACKGROUND: During early clinical development, prospective identification of a predictive biomarker and validation of an assay method may not always be feasible. Dichotomizing a continuous biomarker measure to classify responders also leads to challenges. We present a case study of a prospective–ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendell, Jeanne, Freeman, Daniel J., Feng, Wenqin, Hettmann, Thore, Schneider, Matthias, Blum, Sabine, Ruhe, Jens, Bange, Johannes, Nakamaru, Kenji, Chen, Shuquan, Tsuchihashi, Zenta, von Pawel, Joachim, Copigneaux, Catherine, Beckman, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484825/
https://www.ncbi.nlm.nih.gov/pubmed/26137564
http://dx.doi.org/10.1016/j.ebiom.2015.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484825/
https://www.ncbi.nlm.nih.gov/pubmed/26137564
http://dx.doi.org/10.1016/j.ebiom.2015.02.005

Ejemplares similares